Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: GIII stock price vs ANIP: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ANIP's multiple
Needs ANIP P/E.
Implied fair value · at GIII's multiple
Needs GIII P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: GIII FY 2026 (ended Jan 31, 2026) · ANIP FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 99% equity / 1% debt · EV / Revenue 0.26x · EV / EBITDA 5.42x
Capital structure 84% equity / 16% debt · EV / Revenue 1.84x · EV / EBITDA 7.53x
ANIP carries the larger enterprise value at $1.63B against $775.45M; GIII trades on the lower EV / Revenue multiple (0.26x vs 1.84x); GIII on the lower EV / EBITDA (5.42x vs 7.53x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
G III APPAREL GROUP LTD /DE/ · implied price per share
Bear
$81.16
Base
$93.91
Bull
$110.53
ANI PHARMACEUTICALS, INC · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.01x
0.57x
Net debt / EBITDA
Leverage against operating earnings
-2.76x
0.11x
Cash and equivalents
Liquid reserves on the balance sheet
$406.66M
$285.59M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LEVI STRAUSS & CO
GIII vs LEVI
Capri Holdings Ltd
GIII vs CPRI
TAPESTRY, INC.
GIII vs TPR
AMERICAN EAGLE OUTFITTERS INC
GIII vs AEO
SUPERNUS PHARMACEUTICALS, INC.
GIII vs SUPN
PERRIGO Co plc
GIII vs PRGO
Viatris Inc
GIII vs VTRS
Organon & Co.
GIII vs OGN
TEVA PHARMACEUTICAL INDUSTRIES LTD
GIII vs TEVA
$11.74M
$309.11M
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
